A recent drug is about to begin a revolution in the burden loss industry. Mounjaro is on its method to getting approval from authorities after showcasing promising results during trials.

Eli Lilly’s tirzepatide, brand name Mounjaro, is already approved by the Food and Drug Administration (FDA) for type 2 diabetes. However the drugmaker is in search of its approval as a weight reduction drug.

Cleveland Clinic cardiologist Steven Nissen, M.D., currently leads a study into Mounjaro as a weight reduction solution, and he’s raving concerning the drug’s potential based on preliminary data.

“We’re really entering a totally recent era now, where for the primary time, we’ve got drugs for obesity that really work,” he told WKYC in an interview.

Nissen said Mounjaro works like bariatric surgery and produces higher results than similar diabetes drugs for weight reduction, including Wegovy and Ozempic.

“It showed greater than a 20% average weight reduction over 18 months. That is within the range of weight reduction that we only saw with bariatric surgery,” he explained.

For the worldwide study, Nissen and his team are examining some 15,000 patients with obesity. They’re randomly assigned to the Mounjaro or placebo group and undergo counseling.

While Mounjaro appears promising, some experts warned people eager to drop pounds to “be very careful” when taking these kinds of medication. One in every of them is Dr. Steve Heymsfield, a professor within the Metabolism and Body Composition Laboratory on the Pennington Biomedical Research Center of Louisiana State University.

“There’s literally an appetite for drugs like this within the population. Since almost half of Americans are obese, we all know there’s that need for this, but we’ve got to be very cautious with these drugs,” he told KOMO News.

Nevertheless, Eli Lilly is decided to affix the growing market of diabetes drugs for weight reduction, recently telling the press that it’ll ask the FDA to grant a sign for weight management on its drug’s label.

Nissen can also be optimistic that the drug will bring more advantages than simply weight reduction, saying, “There is a superb probability that losing as much body weight as people will lose with this drug will actually reduce cardiovascular events.”

Published by Medicaldaily.com